Skip Navigation


NDT Advance Access originally published online on January 8, 2007
Nephrology Dialysis Transplantation 2007 22(3):684-686; doi:10.1093/ndt/gfl740
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/3/684    most recent
gfl740v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Roger, S. D.
Right arrow Articles by Levin, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roger, S. D.
Right arrow Articles by Levin, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Epoetin trials: randomised controlled trials don't always mimic observational data

Simon D. Roger1 and Adeera Levin2

1Department of Renal Medicine, Gosford Hospital, Gosford 2250, Australia and 2Division of Nephrology, University of British Columbia, Vancouver, BC Canada

Correspondence and offprint requests to: Dr Simon D. Roger, MD, FRACP, Department of Renal Medicine, Gosford Hospital, Gosford 2250, Australia. Email: sroger@nsccah.health.nsw.gov.au

Keywords: anaemia; clinical trials; CHOIR; CREATE; erythropoietin

The first 150 words of the full text of this article appear below.

The medical management of stage 3 and 4 chronic kidney disease (CKD) attempts to both slow the rate of progression towards dialysis and prevent the development of secondary complications associated with worsening uraemia. Clinicians attempt to achieve this by targeting blood pressure, lipids, calcium-phosphate imbalance (mineral metabolism) and anaemia.

Over the past 20 years, there has been a wealth of publications reporting on the associations between uraemic anaemia and the development of left ventricular dilatation and left ventricular hypertrophy (LVH) [1–4], reduced quality of life [5,6] and mortality rates [7], both in the CKD non-dialysis and dialysis populations. In the pre-epoetin era, Silberberg reported an association between the degree of anaemia and LVH and differential mortality rates in dialysis patients in the late 1980s [8]. These findings were extended by Foley and Parfrey et al. [9,10. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

Is early treatment of anaemia with epoetin-{alpha} beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial
Iain C. Macdougall, R. Mark Temple, Jonathan T. C. Kwan, and on behalf of the EPO-GBR-2 Study Group
NDT 2007 22: 784-793. [Abstract] [FREE Full Text]